(AOF) – Genfit announces cash and cash equivalents of 77.8 million euros as of December 31, 2023. The biotech specialist in improving the lives of patients suffering from rare liver diseases that can be life-threatening underlines that this amount does not include the receipt of a milestone payment of €13.3 million in February 2024 from Ipsen. It anticipates that this will allow the financing of its operational and capital expenditures until, approximately, the fourth quarter of 2025.
The turnover for the 2023 financial year amounts to 28.6 million euros compared to 20.2 million euros for the same period in 2022. Of these 28.6 million euros, 13.3 million euros are attributable to the milestone payment invoiced to Ipsen in December 2023 pursuant to the license and collaboration agreement signed in December 2021.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
